home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Events -> Meetings and Conferences  

The Immunotherapies Congress

  May 17, 2013  
Hilton Boston Back Bay, Boston, MA
August 13-15, 2013

Session Titles:

  • The Promise of T Cell Engineering
  • It Takes Two to Tango: Fine Tuning of Tumor Cells and T Lymphocytes for Maximized Anti-Tumor Activity
  • Improved Cancer Immunotherapy through CD134 plus CD137 Dual Co-Stimulation
  • Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy
  • Advances in Biomarker Validation and Trial Design for Antitumor Immunotherapy
  • Exploring Synergy between Targeted Therapy and Immunotherapy
  • Synergism Between Anti-Tumor Antibodies and PK-Extended IL-2
  • Identifying New Cancer Immunotherapy Targets for T Cells
  • Immunomodulatory Antibody-Fusion Proteins for Cancer Immunotherapy
  • TIM (T Cell Immunoglobulin and Mucin)-3 as a Potential Target for Cancer Immunotherapy
  • Allovectin: In vivo Studies and Potential Synergy with other Advanced Melanoma Immunotherapeutics
  • Clinical Update of IL2 Adjunctive Co-Therapy for Suppression of Solid Tumors with Designer T Cells
  • Challenges in Vaccine Therapy for Hematological Malignancies
  • Biomarkers Correlative of Clinical Response to Sipuleucel-T
  • Partnering Therapeutic Vaccines with Large Pharma
  • Clinical Results of Pexa-Vec (JX-594): Multi-Mechanistic Oncolytic Viruses as a Strategy for Cancer Immunotherapy
  • Clinical Update on PROSTVAC, a Therapeutic Vaccine Candidate for Advanced Prostate Cancer
  • Immune Monitoring on Pre-Surgical Clinical Trials with a Novel Checkpoint Blockade Agent, Anti-CTLA-4
  • Preliminary Clinical Efficacy and Safety of MK-3475 (Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Melanoma
  • Development of Immunomodulatory PD-1 Antibodies in Renal Cell Carcinoma
  • Anti-PD-1 Antibody Therapy for B-Cell Lymphoma
  • AMP-224, A Fusion Protein with Potential to Modulate the PD-1 Pathway
  • Immunocytokines: A Novel Potent Class of Armed Antibodies
  • Mechanism of Action and Progress Update for MGA271: An Fc-Enhanced mAb Targeting B7-H3 in Solid Tumors
  • Preclinical Update: Development of a Human Anti-CD27 Monoclonal Antibody as a Potential Cancer Therapy
  • Targeting CD47-SIRPa Interactions for Potentiating Antibody Therapy in Cancer
  • Clinical Trials Design for Cancer Immune Therapies
  • Characteristics and Management of Immune-Related Adverse Effects Associated with Ipilimumab, a New Immunotherapy for Metastatic Melanoma
  • Safety Challenges to Development of Immune System Activating Antibodies
  • MCLA-117: ABiclonics – ENGAGE Bispecific IgG Product Lead Targeting CLEC12A and CD3 in AML
  • Bispecific Antibody Targeting CD47 Aiming at Increasing Phagocytosis of Cancer Cells


Organized by: Cambridge Healthtech Institute
Invited Speakers:
  • Adam J. Adler, Ph.D., Associate Professor of Immunology, University of Connecticut
  • Michel Sadelain, M.D., Ph.D., Director, Center for Cell Engineering & Gene Transfer and Gene Expression Laboratory, Memorial Sloan-Kettering Cancer Center
  • Daniel J. Powell, Jr., M.D., Assistant Professor, Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania
  • Rakesh K. Jain, Ph.D., Andrew Werk Cook Professor of Tumor Biology, Harvard Medical School; Director, E.L. Steele Laboratory of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital
  • Susan R. Slovin, M.D., Ph.D., Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan–Kettering Cancer Center
  • Zachary Cooper, Ph.D., Postdoctoral Research Associate, Surgical Oncology, Massachusetts General Hospital
  • John Doukas, Ph.D., Senior Director, Preclinical Safety and Efficacy, Vical, Inc.
  • K. Dane Wittrup, Ph.D., Dubbs Professor, Chemical Engineering and Biological Engineering, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
  • Robert Holt, Ph.D., Senior Scientist and Head of Sequencing, British Columbia Cancer Agency, Canada
  • Dafne Müller, Ph.D., Researcher, Institute of Cell Biology and Immunology, University of Stuttgart, Germany
  • Ana Carrizosa Anderson, Ph.D., Assistant Professor, Neurology, Harvard Medical School
  • Richard P. Junghans, M.D., Professor, Department of Medicine, Boston University School of Medicine; Roger Williams Medical Center
  • Anne Moon, Ph.D., Vice President, Product Development, Jennerex
  • David E. Avigan, M.D., Associate Professor, Medicine, Harvard Medical School; Director, Hematologic Malignancy/Bone Marrow Transplant Program, Beth Israel Deaconess Medical Center
  • James Trager, Ph.D., Vice President, Research, Dendreon
  • Kevin Heller, Global Lead Oncology; Search, Evaluation and Diligence, Bristol-Myers Squibb
  • Alain Delcayre, Ph.D., Vice President, R&D, BN Immunotherapeutics
  • Padmanee Sharma, M.D., Associate Professor, Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
  • Omid Hamid, M.D., Director, Melanoma Center, Angeles Clinic and Research Institute
  • Lauren Harshman, M.D., Assistant Professor, Dana-Farber Cancer Institute
  • Sattva S. Neelapu, M.D., Associate Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
  • Solomon Langermann, Ph.D., CSO, Amplimmune
  • Lawrence J. Thomas, Ph.D., DABT, CMAR, Senior Director, Preclinical Research and Development, Celldex Therapeutics, Inc. 
  • Catherine Hutchinson, Ph.D., Research Scientist, Philochem, Switzerland
  • Paul Moore, Ph.D., Vice President, Cell Biology & Immunology, Macrogenics
  • Timo van den Berg, Ph.D., Head, Blood Cell Research, Sanquin Blood Supply Foundation, The Netherlands
  • Lex Bakker, Ph.D., Chief Development Officer, Merus, The Netherlands
  • Harriet Kluger M.D., Associate Professor, Yale Cancer Center
  • Stephanie Andrews, Oncology Nurse Practitioner, Moffitt Cancer Center
  • Rakesh Dixit, Ph.D., DABT, Vice President, Research & Development, Global Head, Biologics Safety Assessment, Pathology & LAR, MedImmune (AstraZeneca Biologics)
  • Krzysztof Masternak, Ph.D., Head of Biology, Novimmune SA, Switzerland
Deadline for Abstracts: July 19, 2013
Registration: Register Now
E-mail: kwaterman@healthtech.com
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.